Erschienen in:
01.04.2001 | Commentary
Challenges to the development of antigen-specific breast cancer vaccines
verfasst von:
Matthew J Scanlan, Dirk Jäger
Erschienen in:
Breast Cancer Research
|
Ausgabe 2/2001
Einloggen, um Zugang zu erhalten
Abstract
Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms. Methods such as T cell epitope cloning and serological expression cloning (SEREX) have led to the identification of a number target antigens expressed in breast cancer. Improved immunization strategies, such as using dendritic cells to present tumor-associated antigens to T lymphocytes, have been shown to induce antigen-specific T cell responses in vivo and, in some cases, objective clinical responses. An outcome of successful tumor immunity is the evolution of antigen-loss tumor variants. The development of a polyvalent breast cancer vaccine, directed against a panel of tumor-associated antigens, may counteract this form of immune escape.